Welcome to our dedicated page for Conmed SEC filings (Ticker: CNMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to CONMED Corporation’s (NYSE: CNMD) U.S. Securities and Exchange Commission filings, with AI-powered tools to help interpret the information. CONMED files a variety of reports under the Securities Exchange Act of 1934, and its common stock is registered on the New York Stock Exchange under the symbol CNMD, as noted in multiple Form 8-K filings.
For this medical equipment company in the surgical and medical instrument manufacturing industry, SEC filings are a primary source for understanding its financial condition, operating performance and strategic actions. Current reports on Form 8-K disclose events such as quarterly and year-to-date financial results, portfolio optimization steps, changes in directors and executive officers, dividend declarations, and share repurchase authorizations. For example, recent 8-K filings describe the announcement of second and third quarter financial results, the intent to exit gastroenterology product lines, the appointment of a new independent director, the resignation of a director, the declaration of a quarterly cash dividend, and a planned transition of the Chief Financial Officer.
Annual reports on Form 10-K and quarterly reports on Form 10-Q, when accessed through this page, contain detailed financial statements, segment information for orthopedic and general surgery, and discussions of items that are later referenced in non-GAAP reconciliations, such as product rationalization costs, operational optimization consulting fees, executive transition costs, legal matters, contingent consideration fair value adjustments, restructuring and related costs, and other specified items. These filings also provide context for guidance on revenue and adjusted diluted earnings per share that CONMED discusses in its press releases and investor presentations.
In addition to giving direct access to the underlying documents, this page uses AI to summarize key points from lengthy filings, highlight important sections, and surface items related to topics such as portfolio changes, capital allocation decisions, and leadership transitions. Users can review CONMED’s historical and current SEC disclosures here, along with AI-generated insights that explain the significance of each filing in clear language.
CONMED Corp (CNMD): Insider transaction reported. The company’s Executive Vice President & CFO reported selling 3,500 shares of common stock at $43 on 11/06/2025. Following this open‑market sale, the reporting person beneficially owns 1,836 shares, held directly. The filing indicates the report was made by one reporting person.
CONMED (CNMD) reported Q3 2025 results. Net sales were $337.9 million, up 6.7% year over year, led by General Surgery and Orthopedic Surgery. Diluted EPS was $0.09 as net income fell to $2.9 million.
Gross margin declined to 49.2% (down 730 bps). The quarter included $19.7 million of write-offs tied to canceled product lines and discontinued SKUs, $3.7 million of consulting costs in cost of sales, and tariff impacts. Selling and administrative expense rose to $140.3 million, reflecting $5.5 million in operational optimization consulting, expense from contingent consideration fair value changes, and advisory services earlier in the year.
Year to date, operating cash flow was $124.4 million. Cash was $38.9 million and total long‑term debt was $853.0 million, including $60.0 million outstanding under the term loan and $800.0 million of 2.250% convertible notes due 2027. Interest expense decreased to $7.6 million. The company noted DOJ closed its voluntary disclosure matter with no action.
CONMED (CNMD) received a Form 144 notice indicating a planned sale of restricted securities by an affiliate. The filer intends to sell 3,500 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value $150,500.00. The shares are listed on the NYSE, with an approximate sale date of 11/06/2025.
The securities were acquired on 10/31/2025 via restricted stock vesting from the issuer as compensation. As context, shares outstanding were 30,954,963. In the prior three months, the seller reported a sale of 598 shares on 08/07/2025 for $31,365.10.
Form 144 is a notice of proposed sale and does not involve proceeds to the company.
CONMED Corporation furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025. The press release is provided as Exhibit 99.1, dated November 5, 2025.
The company states the information furnished under Item 2.02 and Exhibit 99.1 is not deemed filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other Securities Act filings unless specifically referenced.
CONMED (CNMD) disclosed an insider equity transaction. On 11/04/2025, the General Counsel & Corporate Secretary converted 4,000 RSUs into common stock (code M) at $0 and satisfied taxes by withholding 1,114 shares at $45.71 per share (code F). After these transactions, 2,886 common shares were owned directly. The RSUs are under the 2018 Long‑Term Incentive Plan and vest over two years, 50% after year 1 and 50% after year 2.
CONMED Corp (CNMD) insider transaction: Executive Vice President & CFO Todd W. Garner reported RSU-related activity on 10/31/2025. He acquired 7,500 shares of common stock at $0 upon settlement of restricted stock units (transaction code M), then had 2,164 shares withheld at $44 per share for taxes (code F).
After these transactions, he holds 5,336 shares directly. He also reports 15,227 RSUs as derivative securities beneficially owned following the transactions. Each RSU represents a right to receive one share of common stock. The RSUs are under the Company’s 2018 Long‑Term Incentive Plan, vesting over two years with 33% after year 1 and 67% after year 2.
CONMED Corp (CNMD) director Charles Farkas reported two open-market sales totaling 2,000 shares on 09/12/2025. The filings show a sale of 1,103 shares at $53.535 and a sale of 897 shares at $53.512. The beneficial ownership reported after the transactions is shown as 15,756 shares and 14,859 shares on the respective lines. The Form 4 is signed by Thomas Fistek on behalf of Mr. Farkas by power of attorney on 09/15/2025.
CONMED Corp (CNMD) Form 144 notice: The filer intends to sell 2,000 common shares through Fidelity Brokerage Services (Smithfield, RI) on or about 09/12/2025. The filing reports an aggregate market value of $107,049.37 and total shares outstanding of 30,954,963. The 2,000 shares were acquired from the issuer as compensation: 897 shares vested 06/01/2020, 335 vested 06/01/2023, 302 vested 05/31/2024, and 466 received via stock appreciation right on 09/06/2024. No sales by the reporting person in the past three months are reported. The filer signs the required representation that they are unaware of any undisclosed material adverse information about the issuer.
Kim Kelderman, a director of CONMED Corporation (CNMD), was granted equity awards on 09/08/2025 consisting of 500 restricted stock units (RSUs) and options to purchase 6,227 shares of common stock. The RSUs represent the right to receive one share each and generally vest 100% after one year. The stock options have an exercise price of $53.83, vest 100% one year from the grant date, are exercisable beginning 09/08/2026 and expire 09/08/2035.
Following the reported grants, the filing shows beneficial ownership of 500 shares underlying RSUs and 6,227 option shares, held in a direct capacity. The Form 4 was signed on 09/09/2025 by a power of attorney on behalf of the reporting person.
CONMED Corporation appointed Kim Kelderman to its Board of Directors effective September 8, 2025. He will serve on the Corporate Governance and Nominating Committee and the Strategy Committee, and the Board determined that he meets the independence requirements of the New York Stock Exchange and the company’s own standards.
Kelderman is currently President, Chief Executive Officer, and a director of Bio‑Techne, and previously held senior leadership roles at Thermo Fisher Scientific and Becton Dickinson. As a non‑employee director, he will receive the same annual cash and equity compensation as other non‑employee directors. Upon appointment, he received a prorated equity grant valued at approximately $134,766, consisting of 500 restricted stock units and stock options to purchase 6,227 shares of CONMED common stock at the September 8, 2025 closing price, vesting in full on September 8, 2026.